In the Phase 2 trial, participants on the highest dose of retatrutide (12 mg) lost an average of 24.2% of their total body weight over 48 weeks
Starting with a lower dose and gradually increasing it may help mitigate these effects
Injectable and self-healing carbohydrate-based hydrogel for cell encapsulation
Whos qualified for GLP-1 Bridge program To be eligible, a patient must meet one of these three conditions: Have a body mass index (BMI) of 35 or more Have a BMI between 30-34.99 and at least one of these conditions: Diastolic heart failure (also called heart failure with preserved ejection fraction) Uncontrolled hypertension (high blood pressure) Chronic kidney disease at stage 3a or higher Prediabetes A previous heart attack or stroke Peripheral artery disease with symptoms Or, have a BMI between 27-29.99 and at least one of these conditions: Prediabetes A previous heart attack (also called myocardial infarction) or stroke Blocked arteries in your legs or arms (also called peripheral artery disease) with symptoms Patients are not eligible if they fall into these categories: If they already are covered for a GLP-1 through Part D Have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease, in which case, they may already be covered by their Part D plans This article first appeared on Bridge Michigan and is republished here under a Creative Commons Attribution-NoDerivatives 4.0 International License
As a natural detoxifier, glutathione is an immune system booster and anti-ageing nutrient which protects cells against free radical damage, the cause of many degenerative medical conditions
